Payment overview · 2025
General Payments
$3,323.46
114 reported records · 11 companies
Healthcare provider profile · identity verified
Aron Rubin, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · BROOKLYN, NY · NPI 1396788956
Verified facts
What the public records show
CMS Open Payments records show Aron Rubin, MD received $3,323.46 in general payments during 2025 across 114 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Fasenra, Nucala, Tezspire, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DALIRESP as an associated drug or biological on 54 records involving 42 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Daliresp by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FASENRA as an associated drug or biological on 40035 records involving 10417 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Fasenra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Symbicort by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 33983 records involving 10291 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tezspire by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ofev by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Nucala by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 387 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $635.81 | 19.1% | 25 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $607.31 | 18.3% | 22 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $388.46 | 11.7% | 13 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $369.83 | 11.1% | 10 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $360.16 | 10.8% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $344.45 | 10.4% | 15 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $236.12 | 7.1% | 6 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $153.97 | 4.6% | 7 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $97.99 | 3.0% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $65.84 | 2.0% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $63.52 | 1.9% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,145.53 | 112 |
| Education | $177.93 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., SANOFI-AVENTIS U.S. LLC | $827.98 | 20 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $607.31 | 22 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $421.54 | 14 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $388.46 | 13 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $236.12 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $185.32 | 8 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $159.13 | 7 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $153.97 | 7 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $149.42 | 8 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $65.84 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $64.85 | 3 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.83 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 26 | exact normalized | Medicare Part D |
| FASENRA fasenra |
2025 | Fasenra | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUCALA nucala |
2025 | Nucala | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TEZSPIRE tezspire |
2025 | Tezspire | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 387 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
26 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | DALIRESP open payments reported associated product |
CMS Open Payments — General Payments 54 supporting records · 42 recipient NPIs · example record 1206139572 |
Daliresp · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FASENRA open payments reported associated product |
CMS Open Payments — General Payments 40035 supporting records · 10417 recipient NPIs · example record 1206131346 |
Fasenra · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
56 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 33983 supporting records · 10291 recipient NPIs · example record 1206131392 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
387 | 83 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 387 | 83 |
| Montelukast Sodium | Montelukast Sodium | 207 | 49 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 198 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 30 |
| Breo Ellipta | Fluticasone/Vilanterol | 166 | 41 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 150 | 28 |
| Spiriva Respimat | Tiotropium Bromide | 148 | 26 |
| Azithromycin | Azithromycin | 137 | 65 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 126 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 121 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 112 | 19 |
| Atenolol | Atenolol | 108 | 19 |
| Prednisone | Prednisone | 105 | 77 |
| Eliquis | Apixaban | 100 | 15 |
| Gabapentin | Gabapentin | 99 | 21 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 97 | 23 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 96 | 46 |
| Dexlansoprazole Dr | Dexlansoprazole | 94 | 26 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 90 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 85 | 17 |
| Carvedilol | Carvedilol | 77 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 73 | 41 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 72 | 19 |
| Losartan Potassium | Losartan Potassium | 71 | 14 |
| Synthroid | Levothyroxine Sodium | 70 | suppressed |
| Vascepa | Icosapent Ethyl | 70 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 68 | 17 |
| Roflumilast | Roflumilast | 67 | 14 |
| Torsemide | Torsemide | 67 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 27 |
| Symbicort | Budesonide/Formoterol Fumarate | 56 | 24 |
| Nucala | Mepolizumab | 52 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 50 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 16 |
| Arnuity Ellipta | Fluticasone Furoate | 48 | 18 |
| Fasenra | Benralizumab | 48 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 47 | suppressed |
| Jardiance | Empagliflozin | 46 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 46 | 11 |
| Lisinopril | Lisinopril | 46 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 44 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 43 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 38 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 38 | 26 |
| Dulera | Mometasone/Formoterol | 35 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Omeprazole | Omeprazole | 31 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Famotidine | Famotidine | 28 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 26 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 24 |
| Lidocaine | Lidocaine | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Simvastatin | Simvastatin | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | 22 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Metformin Hcl | Metformin Hcl | 23 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 19 |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 19 | 11 |
| Glipizide | Glipizide | 19 | suppressed |
| Lexapro | Escitalopram Oxalate | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | suppressed |
| Daliresp | Roflumilast | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 18 | suppressed |
| Alvesco | Ciclesonide | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Nexium | Esomeprazole Magnesium | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | 12 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Furosemide | Furosemide | 14 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | 11 |
| Repaglinide | Repaglinide | 14 | suppressed |
| Xeljanz | Tofacitinib Citrate | 14 | suppressed |
| Azor | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Tezspire | Tezepelumab-Ekko | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Dupixent Pen | Dupilumab | 12 | suppressed |
| Fasenra Pen | Benralizumab | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Ofev | Nintedanib Esylate | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Ryaltris | Olopatadine Hcl/Mometasone | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Asmanex Hfa | Mometasone Furoate | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,323.46 · 114 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Arikayce, Brinsupri, DUPIXENT, FASENRA, JASCAYD, NUCALA, Ohtuvayre, SMARTVEST, TEZSPIRE, TRELEGY ELLIPTA, Vest Therapy Und, YUPELRI | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error